José Batista da Costa

MD Urologist

[francois rozet @rozetfrancois]

2years of ADT after radical prostatectomy for high Risk #prostate #cancer patients did not improve MFS in phase III RCT AFU-GETUG 20 trial. #GU25
Need to identify better biomarkers of relapse @AFUrologie @GETUG_Unicancer @delataillealex @MRoupret @GPloussard

[The Lancet Oncology @TheLancetOncol]

NOW OF: 5-year survival endpoints from the VESPER phase 3 RCT of perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer.

https://t.co/Trtb2Wp6La

[Marc-Olivier Timsit, MD, PhD @UrologieParis]

Heart transplantation after Circulatory Death (vs Brain death)
❇️🫀randomized trial in ⁦@NEJM⁩

✅No difference in patient survival at 6 months (Primary Outcome)

⚠️Severe primary dysfunction :15% vs 5%
✅Primary graft failure : 0% vs 2%
https://t.co/kVsC8jwdsj

[Benjamin Pradere @BenjaminPradere]

🚨Preliminary results of the SUNRISE-1 🌅 study using TAR-200 🥨 (Gemcitabin) @siadaneshmand
➡️in BCG unresponsive

✨Promising results ✨
👉 72.7% of overall CR with TAR-200
👉cetrelimab does % (similar to Pembro KN057)

Gem is a great drug

#AUA23

[George Stagg @gwstagg]

For those R fans waiting patiently for a version of https://t.co/BU41Yx78QT for R, here is a little sneak preview of the progress we've made recently. This is a screen capture showing an editable R Shiny app, running without a Shiny server, via Shinylive and webR😀 #RStats #wasm

[Yüksel Ürün @DrYukselUrun]

🌍 Bladder cancer trends & challenges:
-Rising global incidence 💹
-Need to reduce burden on healthcare systems 🏥
-Increase awareness of risk factors & symptoms 🚨
-Strengthen tobacco control policies 🚭
-Develop less-invasive, affordable diagnostic methods 🩺
-Investigate lifestyle factors & outcomes 🔍 #BladderCancerAwareness @BladderCancerUS @OncoAlert @NatRevClinOncol @Uroweb @myESMO @ASCO @AmericanCancer @NCIprevention
https://t.co/59Vq3ERlpG

[Enrique Grande @drenriquegrande]

⚡️ Out on @NatureComms - Bladder cancer organoids as a functional system to model different disease stages and therapy response

#bladdercancer @paola_gasperini @FrancescaBZNY @Roland3097 @evacomperat @MariannKruithof
⁩
https://t.co/szSqh6JNBz

[Matthieu Boisson @BoissonMatthieu]

Publication dans @JAMANetwork d'une vaste enquête sur l'état psychologique des hospitalo-universitaires 🇫🇷
Symptômes de :
- Burn Out sévère 40%
- Idées suicidaires 14%

41% des MCUPH/29% des PUPH déclarent envisager un changement de carrières !

On attend quoi pour réagir ???

[SPILF @SPILF_]

La @SPILF_ réaffirme que restreindre l’accès aux soins des populations les plus fragiles et les plus précaires quelque soit leur statut administratif est un non sens en termes de santé publique, en termes économique.

https://t.co/CLzjOttuhT

[Enrique Grande @drenriquegrande]

⚡️ Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

@brian_rini @DrChoueiri @montypal @jitcancer #kidneycancer

https://t.co/G8gpuf9peN

[d'Lëtzebuerger Land @Letzland]

„Sie bleiben ein Mann“, versicherte der Arzt während einer Beratung. @Ste_Maj über den neuen "Verhütungstrend" Vasektomie im @Letzland (Zeichnung: Patrick Krombach)

[Association Française d'Urologie - AFU @AFUrologie]

#CFU2022 @pr_gfournier transmet le témoin à @delataillealex le nouveau président de l’@AFUrologie. Félicitations à tous deux 👏

[Antton Rouget @AnttonRouget]

📸@Mediapart publie des photos du dernier «dîner des sommets» de @laurentwauquiez.

Service à la cloche, un serveur par convive, magnums de champagne,...

Débauche de faste, au frais du contribuable👇
https://t.co/EpfIc3Hw5x

[Oded Rechavi @OdedRechavi]

Presenting the same data in every conference for a few years until your new lab generates new results
https://t.co/o6DRDRO98p

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Let the debates start (again!)

PHOTO: Randomized trial
PDD-guided TURBT did not reduce recurrence rates, nor was it cost-effective compared with WL at 3 years @NEJMEvidence @ParamMariappan @EmmaHall71
@BAUSurology @siadaneshmand

#bladdercancer

https://t.co/HZ9lzsMzTd

[Rafael Sanchez-Salas @RSanchez_Salas]

Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis https://t.co/SoQFQ2DyFK. Treatment intensification with ADT back on the spotlight. Systemic therapy becomes essential on PCa

[Yüksel Ürün @DrYukselUrun]

🔶1/5 of the patients with mutations in tumor sequencing have germline mutation, too.
🔶They may have high risk for inherited cancer syndrome and genetic counseling should be provided.
@EUplatinum @OncoAlert @APCCC_Lugano @MSKCancerCenter @ASCO @myESMO
https://t.co/9TN5bf0sxr

[Yüksel Ürün @DrYukselUrun]

🧬SPOP mutations were associated with improved outcomes to ADT+androgen receptor-axis-targeted therapies (but not ADT plus docetaxel) in de novo mCSPC
🔶Treatment selection for mCSPC might be chosen accordingly!
@umangtalking @OncoAlert #prostatecancer
https://t.co/yZWQzxew7h

[Joaquin Mateo @quimmateo]

A brief piece with @mishabeltran to reflect on knowledge gaps for adopting genomic profiling in advanced #prostatecancer patient care – click for #openaccess @EurUrolFocus @PCF_Science https://t.co/Gy6b6ABhpv

[Karim Bensalah @kbensalah35]

Artificial intelligence could help predict recurrence after surgical removal of RCC. Great collaborative french effort.
@ZineEddineKhene @uroccr @UrologieRennes

https://t.co/a1tSybPDp6